surmount-1 tirzepatide weight loss percent 72 weeks for Obesity Treatment and Diabetes Prevention Tirzepatide for the Maintenance of

8(8): p

Choose Retatrutide If: Maximum weight loss is the primary goal Previous GLP-1 agonists produced significant nausea (GIP component may help) No specific liver health concerns requiring treatment Tolerance for slightly higher GI side effects during titration Response to dual agonists (like tirzepatide) has been positive Choose Survodutide If: Liver health concerns exist (fatty liver, MASH, elevated liver enzymes) Moderate weight loss goals rather than maximum efficacy priority Interest in potential cardiovascular outcome benefits (CVOT data pending) Preference for a compound with FDA Breakthrough Therapy designation Plans to potentially transition to approved medication once available For most people focused primarily on weight loss, Retatrutide presents the stronger option based on available data

We would welcome the opportunity to connect and explore how behavioral and trauma-informed tools might strengthen long-term outcomes for people using GLP-1 therapies

Taken together, the above finding indicates that RAS is involved in stress and that inhibiting RAS reduced the effects of stress

3b and 4f), further suggesting a reduction in de novo lipogenesis in the liver